Health Secretary Xavier Becerra said earlier this year that the drugs would be selected from a list of the 50 most expensive for Medicare Part D. The selection process included the drug having been on the market for at least seven years without generic competition, or 11 years in the case of biological products such as vaccines, CNBC reports.